ArticleJugan geon-gang gwa jilbyeong2025
Diagnostic and Treatment Status of Severe Fever with Thrombocytopenia Syndrome in a Patient Cohort in 2022-2024.
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Severe fever with thrombocytopenia syndrome (SFTS) is a notifiable category III infectious disease caused by the SFTS virus ( Methods: This multicenter registry study was conducted between March 2022 and December 2024 across 23 hospitals and included both prospective and retrospective cohorts. Clinical data and biospecimens from the enrolled patients were collected and analyzed to evaluate diagnostic and therapeutic patterns. Results: A total of 311 patients (100 prospective; 211 retrospective) were enrolled, accounting for 15% of all reported cases nationwide (n=2,065). Laboratory confirmation was achieved in 98.4% (306/311) of patients through regional public health laboratories. The median interval from symptom onset to diagnosis was 7 days (interquartile range [IQR], 4-10 days), and 3 days (IQR 1-5 days) from hospital admission to diagnosis. Among confirmed cases, 52.1% (162/311) received treatment, most commonly plasmapheresis, followed by steroids, ribavirin, and intravenous immunoglobulin. Conclusions: This multicenter cohort study characterized the diagnostic and therapeutic patterns of patients with SFTS in ROK. The findings provide essential data for the development of diagnostic tools and therapeutic strategies and highlight the importance of continued multicenter clinical research on SFTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.